
Elodie Bouaziz-Amar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7602753/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quantifying prion disease penetrance using large population control cohorts. Science Translational Medicine, 2016, 8, 322ra9.	5.8	289
2	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 41.	3.0	121
3	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	4.9	42
4	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	3.9	39
5	Variant Creutzfeldt–Jakob Disease Diagnosed 7.5 Years after Occupational Exposure. New England Journal of Medicine, 2020, 383, 83-85.	13.9	39
6	Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	3.0	33
7	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. Neuroscience, 2019, 420, 136-144.	1.1	25
8	Ghrelin, adipokines, metabolic factors in relation with weight status in school-children and results of a 1-year lifestyle intervention program. Nutrition and Metabolism, 2015, 12, 43.	1.3	24
9	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 88.	3.0	20
10	CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 29.	3.0	19
11	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. Alzheimer's Research and Therapy, 2016, 8, 27.	3.0	18
12	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	1.1	18
13	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open, 2019, 9, e026380.	0.8	17
14	Vitamin D Status, Insulin Resistance, Leptin-To-Adiponectin Ratio in Adolescents: Results of a 1-Year Lifestyle Intervention. Open Access Macedonian Journal of Medical Sciences, 2016, 4, 596-602.	0.1	14
15	Fasting levels of glicentin are higher in Roux-en-Y gastric bypass patients exhibiting postprandial hypoglycemia during a meal test. Surgery for Obesity and Related Diseases, 2018, 14, 929-935.	1.0	13
16	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. Alzheimer's Research and Therapy, 2022, 14, .	3.0	12
17	Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study. Journal of Antimicrobial Chemotherapy, 2021, 76, 743-752.	1.3	10
18	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored forÂCognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897.	1.2	9

Elodie Bouaziz-Amar

#	Article	IF	CITATIONS
19	High-sensitivity quantification of acetylcholine and choline in human cerebrospinal fluid with a validated LC-MS/MS method. Talanta, 2021, 224, 121881.	2.9	9
20	Frontotemporal dementia is the leading cause of "true―Aâ^'/T+ profiles defined with Aβ _{42/40} ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	1.2	8
21	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. Alcoholism: Clinical and Experimental Research, 2021, 45, 561-565.	1.4	8
22	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168.	3.0	7
23	Reduced Reverse Cholesterol Transport Efficacy in Healthy Men with Undesirable Postprandial Triglyceride Response. Biomolecules, 2020, 10, 810.	1.8	6
24	Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: A pilot study. Journal of Neuroimmunology, 2019, 334, 576993.	1.1	5
25	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	0.7	5
26	The neurobehavioral effects of the designer drug naphyrone – an experimental investigation with pharmacokinetics and concentration/effect relationship in mice. Psychopharmacology, 2020, 237, 1943-1957.	1.5	4
27	First European case of Creutzfeldt-Jakob disease with a PRNP G114V mutation. Cortex, 2019, 117, 407-413.	1.1	3
28	The Diagnostic Value of a Short Memory Test: The TNI-93. Journal of Alzheimer's Disease, 2021, , 1-11.	1.2	1
29	Title is missing!. , 2020, 17, e1003289.		0
30	Title is missing!. , 2020, 17, e1003289.		0
31	Title is missing!. , 2020, 17, e1003289.		0
32	Title is missing!. , 2020, 17, e1003289.		0
33	Title is missing!. , 2020, 17, e1003289.		0
34	Title is missing!. , 2020, 17, e1003289.		0
35	Title is missing!. , 2020, 17, e1003289.		Ο